Preclinical Immuno-Oncology Case Study
Immune Cell Analysis of LL2 Syngeneic Mouse Lung Cancer Model Following anti-PD-L1 mAb Treatment
Lung cancer is one of the most common cancers diagnosed worldwide. Although the development of immunotherapies targeting the PD-1/PD-L1 axis has improved the outlook for patients with lung cancer, only a proportion respond. Syngeneic mouse tumour models, such as the LL2 (Lewis Lung) lung cancer model reported here, are used widely to further advance immuno-oncology treatments. The LL2 model is regarded as a ‘cold’ tumour model with low T cell infiltration and high immuno-suppressive myeloid cells thus representing a useful model for the development of novel immunotherapies for immune-cold tumours.
We have established validated immunohistochemistry (IHC) assays for mouse immune markers in FFPE tissues to aid understanding of immune system mechanisms in murine syngeneic tumour models during development of novel immunotherapies for cancer patients.
In this poster, we report on the application of those assays combined with digital image analysis solutions to explore the immune response in the LL2 model to anti- PD-L1 treatment.
Download your copy now.